应用XELOX及FOLFOX4方案治疗进展期胃癌疗效及安全性评价

Curative effect and safety assessment of XELOX and FOLFOX4 chemotherapy regimens for patients with advanced gastric cancer

目的:比较奥沙利铂联合卡培他滨(XELOX方案)与奥沙利铂、亚叶酸钙联合氟尿嘧啶(FOLFOX4方案)治疗进展期胃癌的疗效及安全性。方法:58例进展期胃癌患者分别采用XELOX及FOLFOX4方案进行化疗,化疗后比较两组的临床疗效,包括血清肿瘤标记物浓度及不良反应发生率。结果:在临床有效方面,接受XELOX方案化疗组有效率更高,与接受FOLFOX4方案化疗组比较具有统计学差异(P<0.05);两组化疗后血清肿瘤标记物浓度值较化疗前均有所下降,两组间比较无统计学差异(P>0.05)。在不良反应发生率方面,应用XELOX方案化疗组胃肠道反应发生率明显低于应用FOLFOX4方案化疗组,其差异具有统计学意义(P<0.05)。在骨髓抑制、肝肾功能损害及神经毒性发生率方面,两化疗方案无显著统计学差异(P>0.05)。结论:对于进展期胃癌的治疗,XELOX方案较FOLFOX4方案疗效更好,安全性更高。

Objective：To compare the effects and safety of XELOX and FOLFOX4 chemotherapy regimens in the treatment of patients with advanced gastric cancer. Methods：Fifty-eight patients with advanced gastric cancer were treated with XELOX and FOLFOX4 chemotherapy respectively. The clinical efficacy, the concentration of the various tumor makers and safety were compared. Results：Compared with the group of FOLFOX4, the group of XELOX showed much better clinical effects, with significant statistical difference（P〉0.05）. The serum tumor marker concentration of the two groups was decreased after the neoadjuvant chemotherapy and no significant difference between the two groups was found（P〈0.05）. For the adverse reactions, the incidence of the gastrointestinal reactions showed significant difference（P〈0.05） between the two groups, with lower reactions in the group of XELOX; and no significant differences in the incidence of bone marrow depressions, hepatic and renal functional lesion and neurotoxicity were discovered. Conclusion：In the treatment of advanced gastric cancer, the XELOX chemotherapy regimen is more effective with higher safety than FOLFOX4 chemotherapy.